Abstract: Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: X1 is linear or branched C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-4 alkoxy, C1-4 alkylhydroxy, —CH2F, —N(H)C(O)—O—C1-6 alkyl, and C(OH)(CF3); or X1 together with the N atom of the carbamate forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH

Abstract: The present disclosure relates to methods of treating or preventing cancer (e.g., advanced solid cancer) using Compound No. 1 or Compound No. 2: or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceutical kits suitable for the treatment or prevention.

Abstract: Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: X1 is linear or branched C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-4 alkoxy, C1-4 alkylhydroxy, —CH2F, —N(H)C(O)—O—C1-6 alkyl, and C(OH)(CF3); or X1 together with the N atom of the carbamate forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH

Abstract: Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, NH2, C1-4 alkoxy and C1-4 alkylhydroxy; X2 is selected from the group consisting of H, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X2 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of linear or branched C1-6 alkyl, —C1-4 alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, and C1-4 alkylhydroxy; Y is selected from the group co

Abstract: Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, and 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of OH, halogen, linear or branched C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, —CN, NH2, C1-6 alkoxy, and —C1-6 alkylhydroxy; or X1 together with the N atom of the amide forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, —CN, NH2, C1-6 alkoxy, and C1-4 alkylhydroxy; X2 is selected from the group consisting of hydrogen, C3-6 cycloalkyl, —C6-10 aryl, 5-10 membered heteroaryl, and 4-8 membered heter

Abstract: Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I.

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.

Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

Abstract: The present disclosure relates to compounds of Formula (I?): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Abstract: Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, —C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —CHO, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, —O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, —O-(4-8 membered heterocycloalkyl), —O—C1-4 alkyl-(4-8 membered heterocycloalkyl), —OC(O)—C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substi

Abstract: The present disclosure relates to modified IL-18 polypeptides, compositions comprising modified IL-18 polypeptides, methods of making the same, and methods of using the modified IL-18 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-18 polypeptides. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN?. In some embodiments, the disclosed IL-18 polypeptides induce the production of IFN? without being neutralized by IL-18 binding protein.

Abstract: The present disclosure relates to new compounds of formula I and pharmaceutically acceptable salts and stereoisomers thereof, as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, (e.g., humans).

Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.

Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

Abstract: The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S—L—A??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Abstract: The present invention provides compounds having Ar-V7 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of cancer.

Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.

Abstract: The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors.